Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits
24 avr. 2023 09h00 HE
|
Assertio Holdings, Inc.
SYMPAZAN (clobazam) oral CIV film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and older Oral film delivery from SYMPAZAN® delivers...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07 avr. 2023 16h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., April 07, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Reports Fourth Quarter and Full Year 2022 Financial Results
08 mars 2023 16h01 HE
|
Assertio Holdings, Inc.
Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA Increases to $101.6 Million Cash Flows from...
Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical
06 mars 2023 09h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Announces Exchange Offer of $30 Million of its Currently Outstanding 6.50% Convertible Senior Notes Due 2027
23 févr. 2023 07h14 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today...
Assertio Holdings, Inc. Announces Preliminary Fourth Quarter and Full Year 2022 Results
21 févr. 2023 07h00 HE
|
Assertio Holdings, Inc.
Year-over-Year Net Product Sales Increased at Least 54% for the Fourth Quarter and 41% for the Full Year Cash Flows from Operations Was at Least $26 Million for the Fourth Quarter and $78 Million for...
Assertio to Participate in the 2023 Winter Wonderland Best Ideas Conference
16 févr. 2023 08h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio to Participate in the 2023 SVB Securities Global Biopharma Conference
08 févr. 2023 08h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation
17 janv. 2023 09h00 HE
|
Assertio Holdings, Inc.
SYMPAZAN® (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and olderOral film delivery from SYMPAZAN® delivers...
Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent
09 janv. 2023 16h15 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...